Literature DB >> 10385368

Recombinant retrovirus vectors for the expression of MHC class II heterodimers.

H Shimada1, R C Alexander, S Germana, D H Sachs, C LeGuern.   

Abstract

Class II antigens are critical in determining the fate of vascularized allografts across major histocompatibility differences. We have recently developed a new approach to induce transplantation tolerance in miniature swine by creating MHC class II antigen "molecular chimerism" in bone marrow cells of potential recipients through retrovirus-mediated gene transfer. As part of this project, the ability of a recombinant double-expression vector (ZQ32N) to express MHC class II DQA and DQB was investigated. Flow cytometry analyses of ZQ32N transfected virus-producer cells demonstrated the cell surface expression of DQa/DQb heterodimers, thus suggesting a correct transcription, translation, and transport of the swine polypeptides to the cell surface. The analyses of RNA isolated from virus particles produced from ZQ32N transfected virus-producer cells indicated the DQ sequences to be correctly packaged. However, the DQ-negative cells transduced with the ZQ32N retrovirus did not show any DQ-retrovirus surface expression. Southern and Northern blot analyses of ZQ32N transfected and transduced cells strongly suggested DNA rearrangements and deletions which could account for transgene expression loss. An analysis of transduced cell genomes suggested DNA recombinations targeted to homologous sequences within the recombinant provirus. The implications of the sequence instability in designing vectors for gene therapy of organ transplantation are discussed.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10385368     DOI: 10.1007/BF02482348

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  37 in total

Review 1.  Retroviral vectors.

Authors:  A D Miller
Journal:  Curr Top Microbiol Immunol       Date:  1992       Impact factor: 4.291

2.  Structure and expression of class II alpha genes in miniature swine.

Authors:  F Hirsch; S Germana; K Gustafsson; K Pratt; D H Sachs; C Leguern
Journal:  J Immunol       Date:  1992-08-01       Impact factor: 5.422

3.  Expression of human class II major histocompatibility complex antigens using retrovirus vectors.

Authors:  A J Korman; J D Frantz; J L Strominger; R C Mulligan
Journal:  Proc Natl Acad Sci U S A       Date:  1987-04       Impact factor: 11.205

4.  CAT constructions with multiple unique restriction sites for the functional analysis of eukaryotic promoters and regulatory elements.

Authors:  B Luckow; G Schütz
Journal:  Nucleic Acids Res       Date:  1987-07-10       Impact factor: 16.971

5.  Stably transmitted triple-promoter retroviral vectors and their use in transformation of primary mammalian cells.

Authors:  R W Overell; K E Weisser; D Cosman
Journal:  Mol Cell Biol       Date:  1988-04       Impact factor: 4.272

6.  Class II genes of miniature swine. IV. Characterization and expression of two allelic class II DQB cDNA clones.

Authors:  K Gustafsson; C LeGuern; F Hirsch; S Germana; K Pratt; D H Sachs
Journal:  J Immunol       Date:  1990-09-15       Impact factor: 5.422

Review 7.  Retrovirus-mediated transfer of MHC class II cDNA into swine bone marrow cells.

Authors:  C LeGuern; H Shimada; D W Emery; S Germana; G E Shafer; D H Sachs
Journal:  J Mol Med (Berl)       Date:  1995-06       Impact factor: 4.599

Review 8.  Tolerance to primarily vascularized allografts in miniature swine.

Authors:  P Gianello; J M Fishbein; D H Sachs
Journal:  Immunol Rev       Date:  1993-06       Impact factor: 12.988

9.  Transplantation in miniature swine. VIII. Recombination within the major histocompatibility complex of miniature swine.

Authors:  L R Pennington; J K Lunney; D H Sachs
Journal:  Transplantation       Date:  1981-01       Impact factor: 4.939

10.  Preparation and characterization of monoclonal antibodies reactive with porcine PBL.

Authors:  M D Pescovitz; J K Lunney; D H Sachs
Journal:  J Immunol       Date:  1984-07       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.